Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 2
2007 1
2011 4
2012 2
2013 1
2015 7
2016 2
2017 3
2018 5
2019 2
2020 2
2021 2
Text availability
Article attribute
Article type
Publication date

Search Results

29 results
Results by year
Filters applied: . Clear all
Page 1
Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study.
Herbst RS, Redman MW, Kim ES, Semrad TJ, Bazhenova L, Masters G, Oettel K, Guaglianone P, Reynolds C, Karnad A, Arnold SM, Varella-Garcia M, Moon J, Mack PC, Blanke CD, Hirsch FR, Kelly K, Gandara DR. Herbst RS, et al. Among authors: semrad tj. Lancet Oncol. 2018 Jan;19(1):101-114. doi: 10.1016/S1470-2045(17)30694-0. Epub 2017 Nov 20. Lancet Oncol. 2018. PMID: 29169877 Free PMC article. Clinical Trial.
Molecular Insights in Transmission of Cancer From an Organ Donor to Four Transplant Recipients.
Atreya CE, Collisson EA, Park M, Grenert JP, Behr SC, Gonzalez A, Chou J, Maisel S, Friedlander TW, Freise CE, Shoji J, Semrad TJ, Van Ziffle J, Chin-Hong P. Atreya CE, et al. Among authors: semrad tj. J Natl Compr Canc Netw. 2020 Nov 2;18(11):1446-1452. doi: 10.6004/jnccn.2020.7622. Print 2020 Nov. J Natl Compr Canc Netw. 2020. PMID: 33152701
Oxaliplatin-DNA Adducts as Predictive Biomarkers of FOLFOX Response in Colorectal Cancer: A Potential Treatment Optimization Strategy.
Zimmermann M, Li T, Semrad TJ, Wu CY, Yu A, Cimino G, Malfatti M, Haack K, Turteltaub KW, Pan CX, Cho M, Kim EJ, Henderson PT. Zimmermann M, et al. Among authors: semrad tj. Mol Cancer Ther. 2020 Apr;19(4):1070-1079. doi: 10.1158/1535-7163.MCT-19-0133. Epub 2020 Feb 6. Mol Cancer Ther. 2020. PMID: 32029633 Free PMC article.
Randomized Phase 2 Study of Trebananib (AMG 386) with or without Continued Anti-Vascular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma Who Have Progressed on Bevacizumab, Pazopanib, Sorafenib, or Sunitinib - Results of NCI/CTEP Protocol 9048.
Semrad TJ, Groshen S, Luo C, Pal S, Vaishampayan U, Joshi M, Quinn DI, Mack PC, Gandara DR, Lara PN. Semrad TJ, et al. Kidney Cancer. 2019 Feb 5;3(1):51-61. doi: 10.3233/KCA-180041. Kidney Cancer. 2019. PMID: 30854497 Free PMC article.
29 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page